With this aim we reinvestigated seven patients who were not cured by splenectomy and offered splenunculectomy to those with persistent bruising in whom an accessory spleen was shown.
Methods
Platelets were labelled with "'In-oxine under aseptic conditions. Eight MBq of labelled platelets were injected intravenously and anterior and posterior abdominal scintigraphs obtained at one hour and one, two, and three days with a gammacamera.
Patients
The seven patients were aged between 4 and 12 years (mean 8 years) at the onset of the purpura. Splenectomy was performed between one and four years (mean two years) after diagnosis. The response to splenectomy in the seven patients is shown in the Figure. Despite clinicians' enthusiasm for removing accessory spleens, this operation has produced a remission in less than a third of cases presenting up to 1981.3 Application of our criteria to these cases suggests that half of those with true relapses of idiopathic thrombocytopenic purpura responded while none who failed to respond to splenectomy did. To this latter group may now be added our own two patients. In 1981 Pawelski et al5 described 12 patients with apparently true relapses of the purpura after splenectomy, all of whom were cured by splenunculectomy.5
Purpura that fail to respond to splenectomy should be distinguished from true post splenectomy relapses. This has not been the case in the past. Although the number of children not cured by splenectomy in our centre is small, we believe that criteria such as ours (platelets <150x 109/l within six weeks of splenectomy) may identify a group of patients very unlikely to respond to splenunculectomy. Patients who have had a true relapse of the purpura after apparently successful splenectomy in whom an enlarged accessory spleen is shown may well benefit from its removal.
Pancytopenia caused by iron-dextran H HURVITZ, E KEREM, E GROSS-KIESELSTEIN, A BRAND, AND D BRANSKI
Department of Pediatrics, Bikur Cholim General Hospital, Jerusalem, Israel SUMMARY Pancytopenia after intramuscular irondextran treatment occurred in an infant with Down's syndrome. Haematological abnormalities recurred on subsequent challenge. Positive migration inhibiting factor and mast cell degranulation tests support an allergic pathogenesis for the pancytopenia. These side effects have not been reported previously.
Severe, even fatal, allergic reactions are known to occur after parenteral administration of irondextran (Imferon). We describe a patient who developed thrombocytopenia, leucopenia, and haemolytic anaemia after intramuscular injection of iron-dextran. These haematological abnormalities recurred on subsequent challenge.
Case report A 1 year old girl with Down's syndrome was admitted to our department. Blood count showed an iron deficiency anaemia with haemoglobin concentration 83 g/l, packed cell volume 0-28, mean corpuscular volume 71 fl, leucocytes 8x109/l (70% neutrophils, 12% band forms, 16% lymphocytes, 2% monocytes), and platelets 165 x 109/l. Serum iron concentration was 2-3 mM/l (12-7 [tg%) . Iron binding capacity was 55 mM/l (307 ,ug%). Intramuscular iron-dextran (30 mg/kg) was given in three divided doses over six days because of feeding problems and poor compliance. Ten days later the haemoglobin concentration rose to 98 g/l, and the reticulocyte count was 4-8%. The leucocyte count was 9-7x109/l with normal differential count, and the platelet count was 180x 109/l. She was discharged home but was readmitted to hospital one month later. Her blood count showed pancytopenia with haemoglobin concentrations 74 g/l, packed cell volume 0-24, mean corpuscular volume 85 fl, leucocytes 3-3 x 109/l (49% neutrophils, 4% band forms, 43% lymphocytes, 2% monocytes, and 2% eosinophils), and platelets 50x 109/l (Figure) . Direct and indirect Coombs' tests were negative, her glucose-6-phosphate concentration was normal, and thrombocytopenic purpura. 
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